|

Lung Cancer Clinical Trials in New Jersey

164 recruiting studies across 52 cities

All Trials in New Jersey

Phase
Trial Phase Location
A Registry for People With Lung Cancer—Basking Ridge
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal MesotheliomaPhase 2Basking Ridge
A Study of Armored CAR T Cells in People With CancerPhase 1Basking Ridge
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung DiseasePhase 2Basking Ridge
A Study of Hospital-at-Home for People Receiving TarlatamabN/ABasking Ridge
A Study of Intensity-Modulated Pleural Radiation Therapy (IMPRINT) in People With Thymic Cancer That Has Spread to the Lining of the Lungs and ChestPhase 2Basking Ridge
A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung CancerPhase 1/2Basking Ridge
A Study of Ivonescimab in People With Non-Small Cell Lung CancerPhase 1/2Basking Ridge
A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung CancerPhase 1/2Basking Ridge
A Study of Lung Cancer Risk—Basking Ridge
A Study of Lung Cancer Screening in People With Unexplained Weight Loss—Basking Ridge
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft TissueN/ABasking Ridge
A Study of Sacituzumab Govitecan in People With MesotheliomaPhase 2Basking Ridge
A Study of Sotorasib in People With Non-Small Cell Lung CancerPhase 2Basking Ridge
A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the BrainPhase 2Basking Ridge
A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the BrainPhase 2Basking Ridge
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After TreatmentPhase 2Basking Ridge
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)Phase 2Basking Ridge
A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung CancerPhase 1Basking Ridge
A Study of Valemetostat in Combination With Atezolizumab in People With Lung CancerPhase 1Basking Ridge
A Study of ZEN003694 in People With Squamous Cell Lung CancerPhase 2Basking Ridge
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.Phase 2Basking Ridge
A Study of a New PET Scanner in People With Cancer—Basking Ridge
A Study of a Side Effects and Resource Navigation Program for People With CancerN/ABasking Ridge
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor ResectionPhase 3Basking Ridge
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With SurgeryPhase 2Basking Ridge
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL ActivityPhase 2Basking Ridge
Extracellular Vesicles and Particles (EVP) as Biomarkers of Recurrence in Non-Small Cell Lung Cancer—Basking Ridge
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of DiseasePhase 2Basking Ridge
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung CancerPhase 2/3Basking Ridge
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung CancersPhase 2Basking Ridge
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung CancerPhase 3Basking Ridge
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung CancerPhase 2Basking Ridge
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)Phase 2Basking Ridge
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM TrialPhase 3Basking Ridge
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung CancerPhase 3Basking Ridge
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung CancerPhase 1/2Basking Ridge
Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural MesotheliomaN/ABasking Ridge
Using E-Nose Technology to Track Treatment Response in People With Non-Small Cell Lung CancerPhase 2Basking Ridge
Using Urine Samples to Identify Lung Cancer—Basking Ridge
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung CancerPhase 1/2Belleville
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)Phase 3Belleville
GEMINI-NSCLC: NSCLC Biomarker Study—Belleville
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7Phase 2/3Belleville
Leveraging the Emergency Department (LEAD) StudyN/ABrick
Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC TrialPhase 3Brick
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLCPhase 3Camden
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)Phase 3Camden
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor TypesPhase 1/2Camden
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerPhase 2Camden
Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation TherapyN/ACamden
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS BronchoscopyN/ACamden
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)Phase 1/2Camden
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])Phase 3Camden
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE TrialPhase 3Cherry Hill
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung CancerPhase 3Cherry Hill
A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCCPhase 1East Brunswick
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid TumorsPhase 1East Brunswick
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung CancerPhase 2East Brunswick
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerPhase 3East Brunswick
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)Phase 1/2East Brunswick
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid TumorsPhase 1East Brunswick
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerPhase 3East Brunswick
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung CancerPhase 2/3East Brunswick
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Phase 2East Brunswick
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Phase 3East Brunswick
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid TumorsPhase 1East Brunswick
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)Phase 1/2East Brunswick
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)Phase 3East Brunswick
DBC-664 in Adult Patients With Solid TumorsPhase 1East Brunswick
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsPhase 1East Brunswick
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLCPhase 1/2East Brunswick
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation—East Brunswick
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid TumorsPhase 1East Brunswick
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid TumorsPhase 1/2East Brunswick
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)Phase 2/3East Brunswick
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsPhase 1East Brunswick
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung CancerPhase 2East Brunswick
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsPhase 1/2East Brunswick
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D MutationPhase 3Edison
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT—Egg Harbor
ATATcH Alternating Treatment Plans for Advanced CancerPhase 2Elizabeth
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics—Englewood
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection—Englewood
Tempus Small Cell Lung Cancer Observational Study (Sculptor)—Englewood
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPhase 1/2Englewood
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Phase 2Flemington
A Study of DB-1310 in Advanced/Metastatic Solid TumorsPhase 1/2Florham Park
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)Phase 3Hackensack
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Phase 1/2Hackensack
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS MutationsPhase 1/2Hackensack
A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)Phase 1Hackensack
A Phase 1 Study of LNCB74 in Advanced Solid TumorsPhase 1Hackensack
A Phase I Study of SIM0505 in Participants With Advanced Solid TumorsPhase 1Hackensack
A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsPhase 1Hackensack
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid TumorsPhase 1/2Hackensack
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid TumorsPhase 1/2Hackensack
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerPhase 2Hackensack
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsPhase 1/2Hackensack
A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant TumorsPhase 1Hackensack
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H MutationPhase 1Hackensack
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)Phase 1Hackensack
A Study of LY4175408 in Participants With Advanced CancerPhase 1Hackensack
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular LymphomaPhase 1Hackensack
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and LymphomasPhase 1/2Hackensack
A Study of ZL-1310 in Subjects With Small Cell Lung CancerPhase 1Hackensack
A Study of ZW251 in Participants With Advanced Solid TumorsPhase 1Hackensack
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D MutationPhase 1Hackensack
A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)Phase 1/2Hackensack
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid TumorsPhase 1/2Hackensack
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.Phase 1Hackensack
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsPhase 1Hackensack
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid TumorsPhase 1/2Hackensack
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid TumorsPhase 1/2Hackensack
CT-95 in Advanced Cancers Associated With Mesothelin ExpressionPhase 1Hackensack
Empathic Communication Skills (ECS) TrainingN/AHackensack
Iscador® P (Mistletoe) Immunotherapy for Recurrent Resectable Osteogenic SarcomaPhase 2Hackensack
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)Phase 1/2Hackensack
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)—Hackensack
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]Phase 3Hackensack
Post-operative Urinary Retention (POUR) Following Thoracic SurgeryPhase 1/2Hackensack
RAPA-201 Therapy of Solid TumorsPhase 1/2Hackensack
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid TumorsPhase 1Hackensack
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Phase 3Hackensack
Support for Cancer Patients Awaiting NewsN/AHackensack
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced CancersPhase 1/2Hackensack
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With OsteosarcomaPhase 3Hackensack
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung CancerPhase 2Manahawkin
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)Phase 2/3Moorestown
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)Phase 2Moorestown
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)Phase 2Moorestown
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid TumorsPhase 1Morristown
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)Phase 3Morristown
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)Phase 3Morristown
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%Phase 3Morristown
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid TumorsPhase 1Morristown
Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung CancerPhase 2Morristown
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung CancerPhase 3Mullica Hill
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1Phase 3Mullica Hill
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening—Mullica Hill
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL CancerPhase 2Mullica Hill
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung CancerPhase 3Neptune City
A Phase 1/1b Study of IAM1363 in HER2 CancersPhase 1New Brunswick
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)Phase 2New Brunswick
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H MutationPhase 1New Brunswick
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsPhase 1/2New Brunswick
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cmPhase 2New Brunswick
Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy—New Brunswick
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung CancerPhase 1New Brunswick
KO-2806 Monotherapy and Combination Therapies in Advanced Solid TumorsPhase 1New Brunswick
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP DeletionPhase 1New Brunswick
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry—New Brunswick
Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)Phase 3New Brunswick
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell CarcinomaPhase 1New Brunswick
Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPPhase 2New Brunswick
TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for HispanicsN/ANew Brunswick
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung CancerPhase 3Paramus
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung CancerPhase 3Paramus
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)Phase 2Paramus
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibPhase 1/2Paramus
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid TumorsPhase 1Princeton
Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid TumorsPhase 1/2Princeton
Collection of Sputum and Labeling for Lung Cancer—Summit
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic AlterationsPhase 3Voorhees Township

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.